G1 Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
G1 Therapeutics, a commercial-stage oncology company, will have CEO Jack Bailey participate in the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021, at 12:45 PM EDT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
G1 Therapeutics, a commercial-stage oncology company, will have CEO Jack Bailey participate in the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021, at 12:45 PM EDT. This event will be held virtually, and the webcast can be accessed via the company's Events & Presentations page. G1 is focused on developing innovative cancer therapies, including COSELA™ (trilaciclib), and has a strong pipeline targeting various solid tumors such as colorectal, breast, lung, and bladder cancers.
Details
News Market Reaction – GTHX
The recorded move for GTHX in the trading session of this news was -4.86%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
RESEARCH TRIANGLE PARK, N.C., April 07, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Executive Officer Jack Bailey will participate in the 20th Annual Needham Virtual Healthcare Conference. The fireside chat will take place on April 14th at 12:45 PM EDT. This meeting is being held virtually, and a live webcast will be accessible on the Events & Presentations page of http://www.g1therapeutics.com.
About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product COSELA™ (trilaciclib). G1 has a deep clinical pipeline evaluating targeted cancer therapies in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.
G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.
Contacts:
Will Roberts
Vice President, Investor Relations & Corporate Communications
919-907-1944
wroberts@g1therapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.